Israel Englander’s NovoCure NVCR Stock Holding History

Israel Englander’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,800	Closed	-$185K	–	6360
2024 Q2	$185K	Buy	10,800 +600	+6%	+$10.6K	﹤0.01%	5168
2024 Q1	$159K	Sell	10,200 -9,200	-47%	-$135K	﹤0.01%	5454
2023 Q4	$290K	Buy	19,400 +8,700	+81%	+$116K	﹤0.01%	4976
2023 Q3	$173K	Buy	10,700 +2,800	+35%	+$80.7K	﹤0.01%	5177
2023 Q2	$328K	Buy	+7,900	New	+$491K	﹤0.01%	4824
2023 Q1	–	Sell	-140,900	Closed	-$10.3M	–	6702
2022 Q4	$10.3M	Buy	+140,900	New	+$10.6M	0.01%	2089
2021 Q2	–	Sell	-16,000	Closed	-$2.12M	–	6914
2021 Q1	$2.12M	Buy	+16,000	New	+$2.53M	﹤0.01%	3476

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Israel Englander's NVCR Position: Q2 2026 in Review

Israel Englander increased its NovoCure (NVCR) stake by 205% in Q2 2026, buying an estimated $2.83M and bringing the position to 278,068 shares worth $4.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3152.

Israel Englander first reported a position in NVCR in Q4 2015 and has held it in 37 quarters since. The position peaked at $21.9M in Q4 2024. 215 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Israel Englander held 278,068 shares of NovoCure worth $4.21M as of Q2 2026.
Israel Englander bought 186,853 NovoCure shares in Q2 2026, an estimated $2.83M.
NovoCure made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3152 holding.
Israel Englander first reported a position in NovoCure in Q4 2015 and has held it in 37 quarters since.
Israel Englander's NovoCure position peaked at $21.9M in Q4 2024.
215 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.